Bivalirudin for percutaneous coronary interventions: development perspective.
Bittl
J A
JA
Ocala Heart Institute, 1511 S.W. 1st Avenue, Ocala, FL, 34474, USA. jabittl@aol.com.
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000379:methods; D000991:Antithrombins / Q000008:administration & dosage*; D003328:Coronary Thrombosis / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D006629:Hirudins / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D006801:Humans; D015994:Incidence; D007262:Infusions, Intravenous; D010446:Peptide Fragments / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic / Q000639:trends*; D011994:Recombinant Proteins / Q000008:administration & dosage*; D012449:Safety; D015996:Survival Rate
D000991:Antithrombins; D006629:Hirudins; D010446:Peptide Fragments; D011994:Recombinant Proteins; C074619:bivalirudin